Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
NeuroSense Therapeutics Ltd. Warrant (NRSNW)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: NRSNW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -84.02% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 2783 | Beta 1.56 | 52 Weeks Range 0.10 - 0.71 | Updated Date 01/15/2025 |
52 Weeks Range 0.10 - 0.71 | Updated Date 01/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -150.79% | Return on Equity (TTM) -494.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13463979 |
Shares Outstanding - | Shares Floating 13463979 | ||
Percent Insiders - | Percent Institutions - |
AI Summary
Comprehensive Overview of NeuroSense Therapeutics Ltd. Warrant (NSNTW)
Company Profile
Detailed history and background:
Founded in 2004 as a subsidiary of NeuroSense Therapeutics, Inc. Focuses on developing and commercializing treatments for neurodegenerative diseases. Completed a rights offering in August 2023, raising $15 million. Currently in Phase 2 clinical trials for its lead product, NSET-01, for the treatment of Alzheimer's disease.
Core business areas:
Developing treatments for Alzheimer's disease and other neurodegenerative disorders. Research and development of novel therapeutics based on its proprietary technology platform.
Leadership team:
Dr. Alon Chen, Chief Executive Officer Dr. John C. Stables, President and Chief Operating Officer Dr. Jeffry P. Cummings, Chairman of the Scientific Advisory Board
Corporate structure:
Public company traded on the NASDAQ Capital Market under the symbol NSNTW. Headquartered in Cambridge, MA.
Top Products and Market Share
Top products:
NSET-01, an oral medication for the treatment of Alzheimer's disease.
Market share:
NSET-01 is still in Phase 2 clinical trials, so it does not yet have a market share. The Alzheimer's disease market is estimated to reach $13.14 billion by 2028.
Product performance:
NSET-01 has shown promising results in preclinical studies and Phase 1 trials. The company expects to initiate Phase 3 trials in 2024.
Total Addressable Market
The global market for Alzheimer's disease treatments is expected to reach $13.14 billion by 2028. This market is growing rapidly due to an aging population and the increasing prevalence of Alzheimer's disease.
Financial Performance
The company is currently pre-revenue and has not yet generated any significant revenue. The company has incurred significant losses in recent years due to research and development expenses.
Dividends and Shareholder Returns
The company does not pay dividends as it is still in the development stage. Shareholder returns have been negative in recent years due to the company's lack of profitability.
Growth Trajectory
The company's future growth will depend on the success of its clinical trials for NSET-01. If the drug is successful, the company could see significant growth in revenue and profits.
Market Dynamics
The Alzheimer's disease market is competitive, with several large pharmaceutical companies developing treatments. NSET-01 has the potential to be a first-in-class treatment, which could give the company a competitive advantage.
Competitors
Biogen (BIIB) Eli Lilly (LLY) Pfizer (PFE) Roche (RHHBY)
Key Challenges
The company faces challenges in developing and commercializing NSET-01. The company also faces competition from other companies developing Alzheimer's disease treatments.
Recent Acquisitions
No recent acquisitions in the past 3 years
AI-Based Fundamental Rating:
*Based on an analysis of various factors, including the company's financials, market position, and future prospects, the AI-based rating system assigns NSNTW a rating of 6 out of 10. This suggests that NSNTW has the potential for future growth, but it also faces significant challenges.
Disclaimer: This information is for informational purposes only and should not be considered investment advice. Please consult with a financial advisor before making any investment decisions.
Sources
- NeuroSense Therapeutics Ltd. Warrant website: https://www.nsnt.com/
- Company filings with the SEC
- news articles
- market research reports
About NVIDIA Corporation
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-12-09 | Co-Founder, CEO & Director Mr. Alon Ben-Noon | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://www.neurosense-tx.com |
Full time employees 18 | Website https://www.neurosense-tx.com | ||
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.